Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Efficacy and Mechanism of IPSRT for Bipolar II Disorder

12 juni 2026 uppdaterad av: First Affiliated Hospital of Zhejiang University

The Efficacy and Mechanism of Different Intervention Strategy for Bipolar II Disorder Patients With Rhythm Disturbance

This project is based on the biphasic instability model and social timing theory, utilizing IPSRT to help regulate social interactions and establish regular daily habits, alleviate emotional symptoms, and prevent. The included patients with bipolar II disorder who did not take medication for the first time or relapsed within the past month were randomly divided into a medication only group (Q group), a only IPSRT group (I group). Group Q received treatment with quetiapine alone (starting at 50mg/day, with an additional 50mg to 300mg/day per week, and the dosage can be flexibly adjusted); Group I received 12 weeks of interpersonal and social rhythm therapy (12 sessions, once a week, 40 minutes each time, with relatively fixed tasks and agendas for each meeting). Compare the changes in various clinical evaluation scales and skin potential before and after treatment, explore the safety and effectiveness of drug therapy and psychotherapy for patients with bipolar II disorder with rhythm disorders, and investigate the potential biological mechanism of IPSRT by collecting data on salivary cortisol and melatonin, peripheral circadian rhythm genes (PER1/PER2/PER3/BMAL1), and magnetic resonance.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

216

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

  • Kina
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310000
        • The First Affiliated Hospital of Zhejiang University
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • 1: a primary diagnosis of bipolar II disorder in accordance with DSM-V criteria, in a current major depressive episode;

    2: scoring ≥17 on the 17-item Hamilton Rating Scale for Depression (HAMD-17)

    3: scoring <12 on the Young Mania Rating Scale (YMRS)

    4: medication-free (≥4 weeks without psychotropics)

    5: with rhythm disturbance, scoring >26 on the Biological Rhythm Interview for Neuropsychiatry (BRIAN)

    6: Understand written language and be able to conduct questionnaire survey

    7: 18 to 60 years old, gender is not limited

    8: the patient voluntarily participates, signs a written informed consent form, is willing to participate in the study and undergo evaluation

    9: Han Chinese

    10: Right-handedness

Exclusion Criteria:

  • 1: diseases that may significantly increase research risks or interfere with the evaluation of results

    2: patients with rapid-cycling bipolar disorder (with >4 episodes within the past year);

    3: any psychiatric or organic mental disorder, bipolar I disorder (BD I), current alcohol or drug dependence, borderline or antisocial personality disorder

    4: patients currently receiving any psychological treatment or melatonin treatment intervention

    5: patients with active suicidal ideation, HAMD-17 item 3 score ≥3

    6: pregnant

    7: patients with metal objects in the body (pacemaker, cochlear implant, implanted teeth, braces, metal foreign bodies, cardiac stent/intravascular coil, orthopedic steel plate, etc.) and other MRI examination contraindications (claustrophobia or inability to cooperate with the examination).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Group Q
Patients received treatment with quetiapine alone (starting at 50mg/day, with an additional 50mg to 300mg/day per week, and the dosage can be flexibly adjusted)
Läkemedel: Quetiapine (drug)
Patients received treatment with quetiapine alone (starting at 50mg/day, with an additional 50mg to 300mg/day per week, and the dosage can be flexibly adjusted)
Experimentell: Group I
Patients received 12 weeks of interpersonal and social rhythm therapy (12 sessions, once a week, 40 minutes each time, with relatively fixed tasks and agendas for each meeting)
Beteende: Psychopharmacological treatment
Patients received 12 weeks of interpersonal and social rhythm therapy (12 sessions, once a week, 40 minutes each time, with relatively fixed tasks and agendas for each meeting)
Andra namn:
  • Interpersonal and Social Rhythm Therapy (IPSRT)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Hamilton Depression Scale (17-items) Total Score Change
Tidsram: Baseline，4，8，12 weeks after treatment
The Hamilton Depression Scale (17-items), is a 17 item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. It's considered the gold standard for rating depression severity and used frequently in clinical trials. Higher HAM-D17 score indicates more severe depression. A reduction of 50% or more in total score from Baseline indicates clinical response.
Baseline，4，8，12 weeks after treatment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change of The Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN) score
Tidsram: Baseline，4，8，12 weeks after treatment
The BRIAN comprises 18 items, which are divided in 3 areas: sleep and social rhythms, activities and eating pattern. The total score ranged from 18 to 72, a higher score suggested a more severe biological rhythm disturbance.
Baseline，4，8，12 weeks after treatment
Neuroimaging
Tidsram: Baseline，12 weeks after treatment
MRI
Baseline，12 weeks after treatment
Skin potential
Tidsram: Baseline，12 weeks after treatment
In a quiet environment, the subject's left hand was pre connected to a portable skin potential acquisition device to collect skin potential signals under different types of emotional stimulation task paradigms. After denoising, 10 time-domain eigenvalues and 8 time-frequency domain eigenvalues were obtained for each task.
Baseline，12 weeks after treatment
Polysomnography
Tidsram: Baseline，12 weeks after treatment
overnight polysomnography
Baseline，12 weeks after treatment
Change of the Brief Social Rhythm Scale (BSRS) score
Tidsram: Baseline，4，8，12 weeks after treatment
The BSRS assess the irregularity with which participants engage in basic daily activities during the workweek and on the weekend, using a scale ranging from 1 (very regularly) to 6 (very irregularly）
Baseline，4，8，12 weeks after treatment
Neuropsychological tests
Tidsram: Baseline，12 weeks after treatment
Software testing (Prisoner's Dilemma game, Social searching task)
Baseline，12 weeks after treatment
Change of Beck Scale of Suicidal Ideation score
Tidsram: Baseline，4，8，12 weeks after treatment
Beck Scale of Suicidal Ideation is a 21-item self-report instrument that detects and measures the intensity of a patient's specific attitudes, behaviors, and suicide plans during the past week. The BSI score ranges from 0 to 63, with higher scores indicating worse outcomes and lower scores indicating better outcomes.
Baseline，4，8，12 weeks after treatment
Change of the Pittsburgh Sleep Quality Index (PSQI) score
Tidsram: Baseline，4，8，12 weeks after treatment
The PSQI is a validated self-report questionnaire assessing sleep quality and disturbance over 1 month, quantifying 7 sleep-related domains, with higher scores indicating worse sleep quality.
Baseline，4，8，12 weeks after treatment
Change of the Young Mania Rating Scale (YMRS) score
Tidsram: Baseline，4，8，12 weeks after treatment
The Young Mania Rating Scale (YMRS) , is a 11 item diagnostic questionnaire used to measure the severity of mania symptom in patients with mood disorders.
Baseline，4，8，12 weeks after treatment
Change of Hamilton Anxiety Scale score
Tidsram: Baseline，4，8，12 weeks after treatment
Hamilton Anxiety Scale is a 17 item diagnostic questionnaire used to measure the severity of anxiety episodes in patients. Each item on the scale is rated on a 5-point scale from 0 (not present) to 4 (severe), with the total score ranging from 0 to 68. The HAMA-17 is often used in clinical and research settings to assess the severity of anxiety symptoms and to evaluate the effectiveness of treatments for anxiety.
Baseline，4，8，12 weeks after treatment
Change of the Sociaty Adaptive Scale score
Tidsram: Baseline，4，8，12 weeks after treatment
SAS is a self-rating scale used to assess an individual's social functioning in areas such as work, study, interpersonal communication, and family life.
Baseline，4，8，12 weeks after treatment
blood
Tidsram: Baseline，12 weeks after treatment
Blood samples are collected to analyze the expression levels of peripheral circadian clock genes (PER1/PER2/PER3/BMAL1).
Baseline，12 weeks after treatment
saliva samples
Tidsram: Baseline，12 weeks after treatment
Saliva is employed for the analysis of cortisol and melatonin
Baseline，12 weeks after treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

First Affiliated Hospital of Zhejiang University

Samarbetspartners

Shanghai Mental Health Center
Second Xiangya Hospital of Central South University
Zhejiang Provincial Tongde Hospital
Brain Hospital Affiliated to Guangzhou Medical University
The Affiliated Hospital of Hangzhou Normal University
Hunan Mental Hospital
First Affiliated Hospital of Kunming Medical University
Brain Hospital Hunan Province

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juli 2026

Primärt slutförande (Beräknad)

1 juli 2029

Avslutad studie (Beräknad)

1 juli 2029

Studieregistreringsdatum

Först inskickad

12 juni 2026

Först inskickad som uppfyllde QC-kriterierna

12 juni 2026

Första postat (Faktisk)

17 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • IIT20250074C-R2

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera